Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
For overlap across multiple ETFs use Portfolio Builder
11
Number of overlapping holdings
22.9%
% of CANC's 48 holdings also in IDNA
23.9%
% of IDNA's 51 holdings also in CANC
Overlap by Weight
Sector Drift (CANC minus IDNA)
Overlapping Holdings
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in CANC |
Weight in IDNA |
Overlap | |
|---|---|---|---|---|
 |
ASTRAZENECA PLC | 4.2% | 5.1% | 4.2% |
 |
REVOLUTION MEDICINES, INC. | 5.7% | 4.0% | 4.0% |
|
EXELIXIS INC | 3.8% | 5.2% | 3.8% |
|
ARCELLX, INC. | 2.9% | 3.8% | 2.9% |
|
MERCK & CO. INC. | 2.7% | 3.9% | 2.7% |
Position Highlights (Non-Overlapping Exposures)
CANC Overweight Relative to IDNA
|
ELI LILLY & CO | 5.4% |
 |
ROCHE HOLDINGS LTD-SPONS ADR | 5.1% |
|
BRIDGEBIO PHARMA, INC. | 4.5% |
|
NOVARTIS AG | 4.3% |
|
BRISTOL-MYERS SQUIBB CO | 4.0% |
|
NUVALENT, INC. CLASS A | 3.9% |
|
SUMMIT THERAPEUTICS INC | 3.9% |
 |
GENMAB A/S SPONSORED ADR | 3.4% |
 |
MERUS N.V. | 3.2% |
 |
ZAI LAB LTD. UNSPONSORED ADR | 3.0% |
CANC Underweight Relative to IDNA
|
BEIGENE, LTD. | -5.8% |
|
ROCHE HOLDING LTD | -5.5% |
 |
SANOFI-AVENTIS | -5.5% |
|
GSK PLC | -5.3% |
 |
TAKEDA PHARMACEUTICAL CO LTD | -5.2% |
|
GENMAB A/S | -4.6% |
|
SPRINGWORKS THERAPEUTICS, INC. | -4.3% |
 |
BIONTECH SE SPONSORED ADR | -4.2% |
|
TWIST BIOSCIENCE CORP. | -3.6% |
|
INCYTE CORP | -3.5% |